Teva Pharmaceutical Industries (TEVA) revenue

Revenue · fiscal 2025
$17.26B

Teva Pharmaceutical Industries (TEVA) reported revenue of $17.26B in fiscal 2025 (the year ended December 31, 2025). That is 4.3% higher than the $16.54B of fiscal 2024. Figures as of 18 Nov 2026, 12:12 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Revenue, fiscal 2025
$17.26B
Change on fiscal 2024
+4.3%
Growth, 5 years
+0.7% a year
Growth, 10 years
−1.3% a year
Highest on record
$21.90Bfiscal 2016
Lowest on record
$9.41Bfiscal 2007
Fiscal years on record
192007–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Teva Pharmaceutical Industries revenue, in more detail

Over the five fiscal years to 2025 revenue grew at a compound 0.7% a year; over ten years the rate was −1.3% a year. Across the 19 fiscal years on record (2007–2025), the highest was $21.90B in fiscal 2016 and the lowest $9.41B in fiscal 2007.

History · 19 fiscal years

Revenue by fiscal year

Teva Pharmaceutical Industries revenue, year by year

Teva Pharmaceutical Industries (TEVA) revenue by fiscal year
Fiscal yearRevenueChangeYear ended
2025$17.26B 4.3% up
2024$16.54B 4.4% up
2023$15.85B 6.2% up
2022$14.93B 6.0% down
2021$15.88B 4.7% down
2020$16.66B 1.4% down
2019$16.89B 7.6% down
2018$18.27B 16.4% down
2017$21.85B 0.2% down
2016$21.90B 11.5% up
2015$19.65B 3.1% down
2014$20.27B 0.2% down
2013$20.31B 0.0% down
2012$20.32B 10.9% up
2011$18.31B 13.6% up
2010$16.12B 0.0%
2009$16.12B 45.4% up
2008$11.09B 17.8% up
2007$9.41B—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement.

How to read it

Steady growth in revenue is the raw material for everything else; a fall means the company is selling less or charging less.

Revenue at health care companies of similar size

Revenue of Teva Pharmaceutical Industries and comparable companies
CompanyRevenueFiscal year
Medline MDLN$28.43B2025
Teva Pharmaceutical Industries TEVA$17.26B2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on TEVA

Teva Pharmaceutical Industries, figure by figure

Teva Pharmaceutical Industries (TEVA) overview: price, valuation and scorecardAll health care companies by market value

Teva Pharmaceutical Industries revenue: questions and answers

What is Teva Pharmaceutical Industries's revenue?

Teva Pharmaceutical Industries (TEVA) reported revenue of $17.26B in fiscal 2025 (the year ended December 31, 2025). That is 4.3% higher than the $16.54B of fiscal 2024.

What is the growth rate of Teva Pharmaceutical Industries's revenue?

Over the five fiscal years to 2025 revenue grew at a compound 0.7% a year; over ten years the rate was −1.3% a year.

What are the highest and lowest revenue figures on record for Teva Pharmaceutical Industries?

Across the 19 fiscal years on record (2007–2025), the highest was $21.90B in fiscal 2016 and the lowest $9.41B in fiscal 2007.

How is Teva Pharmaceutical Industries's revenue calculated?

Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement. For Teva Pharmaceutical Industries it is on record here for 19 fiscal years, 2007 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Teva Pharmaceutical Industries (TEVA) revenue”, data as of 18 November 2026. https://funkfolio.com/stock/TEVA/revenue

Underlying data: the company's filings with the SEC and Yahoo Finance.